Biotinylated Anti‑PTPNS1 Antibody: Research Tools for Dissecting the CD47‑SIRPα Immune Checkpoint Axis

Molecular Characteristics and Cellular Distribution of PTPNS1 (SIRPα / CD172a)

PTPNS1, also annotated as SIRPα, CD172a or SHPS‑1, represents a type‑I transmembrane glycoprotein predominantly expressed across myeloid‑lineage cell populations. Its extracellular segment contains three immunoglobulin‑like domains that mediate physical binding interactions with the widely distributed cell‑surface ligand CD47. Intracellular cytoplasmic regions carry immunoreceptor tyrosine‑based inhibitory motifs to propagate downstream inhibitory signalling after ligand engagement.

The SIRP protein family holds five distinct members: SIRPα, SIRPβ1, SIRPβ2, SIRPγ and SIRPδ. Both SIRPα and SIRPγ can engage CD47 molecules, yet SIRPγ exhibits roughly 10‑fold lower binding affinity toward CD47 in biochemical assay settings. SIRPγ bears a very short cytoplasmic segment consisting of merely four amino‑acid residues with no recognizable signal‑transduction capacity.

For these molecular reasons, SIRPα functions as the primary receptor transmitting inhibitory signals downstream from CD47 ligation within immune‑cell experimental systems. Its expression profile remains largely restricted to myeloid subsets such as macrophages, neutrophils and selected dendritic‑cell populations. This constrained expression makes PTPNS1 a reliable cell‑surface marker for identifying myeloid immune‑cell subgroups in mixed‑cell samples.

Physiological and Pathological Functions Regulated by the CD47‑SIRPα Signalling Axis

CD47 molecules appear on the plasma membrane of most healthy cell types across diverse tissue specimens. Physical contacts between CD47 and myeloid‑expressed SIRPα deliver well‑characterized “don’t‑eat‑me” inhibitory signals to macrophage populations. This molecular circuit preserves immune homeostasis and prevents inappropriate phagocytic clearance of endogenous healthy host cells in physiological contexts.

Tumour cells hijack this conserved homeostatic mechanism by elevating surface CD47 abundance to evade phagocytic removal by innate immune effector cells. In basic‑research hypotheses, effective CD47‑SIRPα axis blockade should boost macrophage‑mediated tumour‑cell engulfment. Enhanced phagocytosis may further support antigen presentation and subsequent CD8⁺ T‑cell‑driven adaptive immune activation in co‑culture experimental models.

Early research programs targeting CD47 mainly prioritized candidate molecules with minimal binding toward erythrocytes to limit hematology‑related toxic phenotypes. Nevertheless, many of these antibody candidates delivered modest functional outcomes in tumour‑relevant pre‑clinical assay panels. These inconsistent observations prompted deeper mechanistic studies examining additional molecular requirements for measurable anti‑tumour‑related immune responses.

Fc‑FcγR Crosstalk: Why Pure Fab‑Mediated Receptor Blockade Is Often Insufficient

Accumulating laboratory findings demonstrate that anti‑CD47 antibody activity depends not only on Fab‑driven disruption of CD47‑SIRPα molecular contacts. Fc‑domain‑mediated engagement with Fcγ receptor (FcγR) families contributes substantially to measurable antibody‑dependent cellular‑phagocytosis readouts. Fcγ receptors fall into two functional groups defined by activating versus inhibitory intracellular signalling outputs.

Binding events between antibody Fc segments and activating‑type FcγR isoforms trigger phagocyte activation and amplify tumour‑cell engulfment within in‑vitro co‑culture setups. Distinct IgG subclasses display variable binding affinity profiles for human FcγRIIA and FcγRIIIA receptor molecules. IgG1 generally shows stronger affinity than IgG2 or IgG4 isoforms for these activating receptor subtypes under test conditions.

Numerous early‑generation anti‑CD47 antibody constructs adopted IgG4 or IgG2 constant‑region frameworks for experimental evaluation. These subclass selections reduced Fc‑dependent ADCP magnitude and may partially explain limited functional responses recorded in pre‑clinical studies. Published work from Cancer Cell reinforces the necessity of synergistic Fc‑FcγR engagement alongside Fab‑mediated ligand‑receptor disruption for robust immune responses.

These mechanistic insights shape modern antibody‑engineering experimental workflows for the CD47‑SIRPα axis. Research‑oriented antibody design must evaluate both Fab‑dependent blocking potency and Fc‑mediated effector functions during candidate‑molecule characterization phases.

Key Laboratory‑Based Research Applications for Biotinylated Anti‑PTPNS1 Antibody

Biotin‑labelled anti‑PTPNS1 antibody supplies versatile detection and functional‑intervention tools for innate‑immunity basic‑research workflows. For immune‑cell‑subset identification, CD172a serves as a myeloid‑lineage marker detectable via streptavidin‑coupled fluorophores or magnetic micro‑bead reagents. This experimental setup supports flow‑cytometry or immunohistochemistry profiling of macrophage and dendritic‑cell subpopulations.

Within receptor‑ligand interaction assays, biotin modification enables high‑sensitivity signal generation built upon classic streptavidin‑biotin molecular recognition. Researchers deploy this reagent to quantify CD47‑SIRPα binding affinity and measure competitive blocking efficiency produced by test antibody candidates in biochemical plate‑based assays.

Function‑perturbation experiments apply anti‑PTPNS1 antibody to interfere with endogenous CD47‑SIRPα signalling contacts. Such neutralization assays help investigators assess this checkpoint’s contributions to macrophage phagocytosis, dendritic‑cell‑T‑cell crosstalk and tumour‑immune‑escape phenotypes. Collectively these assays expand mechanistic understanding of myeloid‑centred immune regulatory networks.

Immune‑Checkpoint Research Reagents from ANT BIO PTE. LTD.

ANT BIO PTE. LTD. provides rat anti‑mouse CD172a (SIRPα) antibody clone S‑R713 for mouse‑relevant immunology laboratory investigations. Two product formats include biotin‑conjugated and unconjugated versions under catalog numbers S0B8321 and S0B5183 respectively. Both reagents have undergone target‑specific validation and strict batch‑to‑batch quality‑control assessment.

These antibody reagents are compatible with flow cytometry, immunohistochemistry and western‑blot experimental workflows. Researchers implement them for myeloid‑cell‑subset profiling, immune‑checkpoint mechanistic exploration and tumour‑microenvironment‑oriented basic‑research projects.

Related Product Portfolio

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.